Preliminary determination of the association between symptom expression and urinary metabolites in subjects with chronic fatigue syndrome. — CFSMEATLAS
Preliminary determination of the association between symptom expression and urinary metabolites in subjects with chronic fatigue syndrome.
McGregor, N R, Dunstan, R H, Zerbes, M et al. · Biochemical and molecular medicine · 1996 · DOI
Quick Summary
Researchers found that ME/CFS patients have a distinctive substance in their urine called CFSUM1 that is rarely found in healthy people. This study examined whether certain chemicals in urine could be linked to the different symptoms ME/CFS patients experience, such as fatigue, cognitive problems, muscle pain, and digestive issues. They discovered that two specific urine metabolites—CFSUM1 and beta-alanine—were strongly associated with symptom severity, suggesting these could eventually be used as biological markers for diagnosing ME/CFS.
Why It Matters
This study provides preliminary evidence that ME/CFS may have measurable biological markers in urine that correlate with symptom patterns, which could lead to objective diagnostic tests rather than relying solely on symptom reporting. Identifying metabolite signatures associated with specific symptom clusters offers insights into the biological mechanisms underlying different ME/CFS presentations and may guide future targeted research.
Observed Findings
CFSUM1 was significantly elevated in ME/CFS patients compared to controls (P < 0.004 for incidence; P < 0.00003 for relative abundance).
Severe fatigue was the only symptom with 100% sensitivity and specificity in distinguishing ME/CFS patients from controls, with CFSUM1 as the primary associated metabolite.
All nine symptom indices (total, core, cognitive, neurological, musculoskeletal, gastrointestinal, infection-related, genitourinary, and pain) were significantly elevated in ME/CFS patients (all P < 0.0000001).
Thirty-three individual symptoms demonstrated significant sensitivity and specificity (P < 0.005) for distinguishing ME/CFS from controls.
CFSUM1 and beta-alanine showed the strongest correlations with the core symptom index, with CFSUM1 primarily linked to infection-related and musculoskeletal symptoms.
Inferred Conclusions
Urinary metabolites, particularly CFSUM1 and beta-alanine, provide a molecular basis potentially useful for developing objective diagnostic tests for ME/CFS.
Different symptom clusters in ME/CFS may be associated with distinct metabolite signatures, suggesting possible biological subtypes or differing pathophysiological mechanisms.
The strong associations between metabolite profiles and symptom expression indicate an underlying biochemical abnormality in ME/CFS that correlates with clinical presentation.
Remaining Questions
What This Study Does Not Prove
This study does not prove that CFSUM1 or beta-alanine cause ME/CFS symptoms or that these metabolites are reliable diagnostic markers—association does not establish causation. The cross-sectional design cannot determine whether metabolite changes precede, follow, or are incidental to symptom development. The small sample size and single time-point measurements limit generalizability and do not establish whether these metabolites would reliably distinguish ME/CFS from other conditions.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Can these metabolite findings be validated in a larger, independent sample, and do they remain stable over time in the same individuals?
Are CFSUM1 and beta-alanine specific to ME/CFS, or do they also appear in other chronic illnesses with similar symptom profiles?
Does the level of these metabolites change with symptom flares or remission, and could they serve as biomarkers for disease progression or treatment response?
What biochemical pathways or physiological mechanisms produce these urinary metabolite changes in ME/CFS patients?